Why Wegovy Outperforms Orlistat for Long-Term Results
Orlistat vs Wegovy Availability: UK Stock Status February 2025
The most significant difference when comparing orlistat vs Wegovy availability is current UK stock levels and accessibility. Orlistat has historically maintained steady supply through multiple generic manufacturers, making it readily available across UK pharmacies. However, Wegovy availability has been limited since its UK launch, creating frustrating delays for patients seeking this more advanced treatment option.
EverydayMeds now maintains complete stock of all five Wegovy doses through our direct Novo Nordisk supply partnership. Unlike many pharmacies experiencing ongoing shortages, we have 0.25mg starter pens, progression doses (0.5mg, 1mg, 1.7mg), and 2.4mg maintenance pens ready for immediate dispatch. This means patients can begin their Wegovy journey without the months-long waiting lists reported elsewhere, making the orlistat vs Wegovy decision based purely on clinical suitability rather than availability constraints.
Orlistat vs Wegovy Pricing: Complete UK Cost Comparison
When evaluating orlistat vs Wegovy costs, the pricing structures differ significantly due to their distinct treatment approaches. Orlistat typically costs £30-50 monthly as a three-times-daily oral medication, whilst Wegovy requires once-weekly injections with dose-dependent pricing. Our Wegovy starter dose (0.25mg) costs £79.99 after applying discount code FIRST40 for new customers, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the maintenance 2.4mg dose.
Our Getting Started bundles provide convenience for the initial dose escalation phase—the Intro Duo (0.25mg and 0.5mg together) costs £169.99, whilst returning customers benefit from discount code DOSE25 at checkout. For patients seeking extended supply security, our Ultimate Stability Trio provides three months of 2.4mg maintenance doses for £649.99. This pricing transparency allows direct orlistat vs Wegovy cost evaluation based on your individual treatment timeline and dose requirements.
Clinical Evidence: Orlistat vs Wegovy Weight Management Outcomes
The clinical evidence base reveals fundamental differences when comparing orlistat vs Wegovy mechanisms and outcomes. Orlistat blocks approximately 30% of dietary fat absorption in the intestines, leading to fat-related side effects if patients consume high-fat meals. The XENDOS study demonstrated average weight loss of 5.8kg with orlistat over four years when combined with lifestyle interventions.
Wegovy operates through GLP-1 receptor agonism, mimicking natural satiety hormones to reduce appetite and promote fullness. In the STEP 1 trial (Wilding et al., NEJM, 2021), patients taking Wegovy alongside diet and exercise experienced approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. The SELECT cardiovascular outcomes trial further demonstrated a 20% reduction in major cardiovascular events, highlighting Wegovy's potential benefits beyond weight management for appropriate patients.
How Wegovy Works: GLP-1 Mechanism vs Orlistat Fat Blocking
Understanding the orlistat vs Wegovy mechanisms helps explain their different side effect profiles and patient experiences. Orlistat works locally in the digestive system, preventing pancreatic lipase enzymes from breaking down dietary fats, resulting in unabsorbed fats being eliminated—often causing oily stools, flatulence, and urgent bowel movements, particularly after high-fat meals. Wegovy functions as a GLP-1 receptor agonist, binding to receptors in the brain's appetite control centres and throughout the digestive system. This mimics glucagon-like peptide-1, a natural hormone released after eating that signals fullness and slows gastric emptying. The result is reduced appetite, smaller portion satisfaction, and decreased food cravings without the fat-malabsorption side effects seen with orlistat.
EverydayMeds Ordering Process: Wegovy Assessment to Delivery
Our streamlined process makes accessing Wegovy significantly simpler than traditional GP routes, addressing the practical considerations in any orlistat vs Wegovy decision. Patients complete our comprehensive 3-minute online clinical assessment, covering medical history, current medications, weight management goals, and previous treatment experiences. Our qualified prescribers review applications within 3 working days (24-hour express review available), ensuring Wegovy suitability based on MHRA licensing criteria including BMI ≥30 or BMI ≥27 with weight-related comorbidities. Once approved, orders are processed through our GPhC-registered pharmacy (#9012878) and dispatched via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements essential for Wegovy stability. This eliminates the typical delays and referral barriers associated with specialist weight management services.
Storage and Practical Considerations: Orlistat vs Wegovy Daily Use
The practical differences between orlistat vs Wegovy extend beyond dosing frequency to storage requirements and lifestyle integration. Orlistat requires three daily doses with meals, stored at room temperature, but necessitates careful dietary fat monitoring to avoid unpleasant side effects—many patients find this restrictive and socially challenging. Wegovy requires refrigerated storage at 2-8°C before first use, but offers significant travel convenience with 6-week room temperature stability below 30°C once removed from refrigeration—superior to Mounjaro's 21-day limit. The once-weekly FlexTouch pen injection takes seconds to administer, with dose escalation from 0.25mg through to 2.4mg maintenance occurring over 16 weeks. This progression allows gradual tolerance development whilst optimising efficacy for individual patients.
Supply Chain Reliability: Why Wegovy Stock Matters in Orlistat vs Wegovy Decisions
Recent orlistat vs Wegovy availability issues have made supply reliability a crucial decision factor for UK patients. Multiple orlistat manufacturers ensure consistent availability, but patients often find limited efficacy disappointing after months of adherence. Wegovy's superior clinical outcomes make it highly desirable, but supply constraints have historically forced patients toward less effective alternatives.
EverydayMeds has invested significantly in Novo Nordisk supply partnerships, maintaining strategic stock levels across all five Wegovy doses. Our supply chain monitoring prevents the stock-outs affecting other providers, whilst our direct manufacturer relationships ensure authentic product sourcing. This reliability means patients can progress through dose escalation without treatment interruptions, maintaining the therapeutic momentum essential for optimal Wegovy outcomes—a critical advantage when comparing orlistat vs Wegovy treatment consistency.
Order Your Wegovy Supply: No Delays, Complete Stock Available
The orlistat vs Wegovy decision ultimately depends on individual clinical needs, lifestyle preferences, and treatment goals—but shouldn't be limited by artificial supply constraints. EverydayMeds provides immediate access to all Wegovy doses through our reliable UK stock, comprehensive clinical assessment, and next-day delivery service. New customers apply discount code FIRST40 at checkout, whilst returning patients use DOSE25 to access our competitive pricing structure. Our clinical team supports your treatment journey from initial assessment through maintenance dosing, ensuring optimal outcomes from this advanced GLP-1 therapy. Visit https://everydaymeds.co.uk/collections/wegovy to begin your assessment today, knowing that your chosen treatment will be available when you need it, backed by our GPhC-registered pharmacy service and expert clinical support.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
